Hypomagnesemia is a common complication of aminoglycoside therapy.
Normal therapeutic dosages of aminoglycosides can cause hypomagnesemia in more than one-third of patients. Hypomagnesemia occurs early in therapy, results in renal Mg++ wasting and may produce hypocalcemia and hypokalemia. Patients who are NPO, eating poorly or not receiving supplemental Mg++ are at high risk for hypomagnesemia. Hypomagnesemia, hypocalcemia and hypokalemia respond to Mg++ replacement therapy. We recommend serial monitoring of serum Mg++ levels in patients receiving aminoglycoside therapy.
D000617:Aminoglycosides / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D007008:Hypokalemia / Q000139:chemically induced; D007239:Infections / Q000188:drug therapy; D008274:Magnesium / Q000652:urine; D008275:Magnesium Deficiency / Q000097:blood / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011863:Radioimmunoassay; D012306:Risk; D013054:Spectrophotometry, Atomic; D013997:Time Factors
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D008274:Magnesium